HIV Drugs Market Growth Trajectory Through 2024-2033

The HIV Drugs by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The HIV Drugs Market:
https://www.thebusinessresearchcompany.com/report/hiv-drug-global-market-report

According to The Business Research Company’s HIV Drugs, The hiv drugs market size has grown steadily in recent years. It will grow from $33.82 billion in 2023 to $35.33 billion in 2024 at a compound annual growth rate (CAGR) of 4.5%. The growth in the historic period can be attributed to increased government support and initiatives, rise in healthcare expenditure, increase in hiv research and development spending, increased incidence of hiv infection, rise in awareness and economic growth in emerging markets.

The hiv drugs market size is expected to see steady growth in the next few years. It will grow to $41.2 billion in 2028 at a compound annual growth rate (CAGR) of 3.9%. The growth in the forecast period can be attributed to increased government support and initiatives, rise in healthcare expenditure, increase in hiv research and development spending, increased incidence of hiv infection, rise in awareness and economic growth in emerging markets. Major trends in the forecast period include investing in 3d bioprinting technology, new product innovations, developing multi-class combination products for hiv treatment and investing in strategic collaborations and agreements.

The novel coronavirus outbreak has augmented the growth of the global HIV drug market. HIV drugs are repurposed to treat Covid 19 infections. Currently, several countries are evaluating and using antiretroviral drugs (For instance, lopinavir boosted with ritonavir (LPV/r)), for treating coronavirus infection.

Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=2834&type=smp

The hiv drugs market covered in this report is segmented –

1) By Type: Nucleoside Reverse Transcriptase Inhibitors (NRT’s), Non- Nucleoside Reverse Transcriptase Inhibitors (NNRT’s), Protease Inhibitors, Integrase strand transfer inhibitors (INSTIs), Other Types
2) By Administration: Oral, Parenteral
3) By Application: Hospital Pharmacies, Retail Pharmacies, Other Applications

The antiretroviral drugs market is increasingly implementing multi-class combination products for the treatment of antiretroviral therapy. Combination drugs combine multiple medications into one drug form. Examples of multiclass combination drugs or single-tablet regimens (STRs) include both NRTIs and NNRTIs: doravirine, lamivudine, and tenofovir disoproxil fumarate (Delstrigo). Based on drug class, drugs are segmented into Integrase Inhibitors, Protease Inhibitors, Multi-class Combination Products, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), and Others. Multi-class Combination Products are the rising burden of HIV and new drug approval. According to WHO, In 2021, 1.5 million [1.1-2.0 million] people contracted HIV, and 650 000 [510 000-860 000] people died from HIV-related causes. Many companies are focusing on developing breakthrough products for the treatment through antiretroviral drugs to maintain their competitive advantage and penetrate new regional markets.

The hiv drugs market report table of contents includes:

1. Executive Summary
2. Market Characteristics
3. Market Trends And Strategies
4. Impact Of COVID-19
5. Market Size And Growth
6. Segmentation
7. Regional And Country Analysis
.
.
.
27. Competitive Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis